

1A.

Figure 1

3p25 breakpoint interval

STS:

D3S1263
NIB1677
D3S3714
D3S3680
WI5650
D3S1259
WI4164
WI7011
WI6652
D3S3701
RAF1
D3S1554
D3S3595
WI3593
AFMCO09ZB9
WI3852
WI7376
WI5975
WI8776
D3S3613
AFMA283XB1
WI7349

PROBES:

753f7

903e6

880h4


59 cR

62-72 cR

932f3

62-72 cR

1B.



1C.



2



3




der(2)



der(3)

Figure 2

2A.



2C.

2B.



2



3



der(2)




der(3)

09710 1199/60

Figure 3

3 A. PAX8-PPAR γ STRUCTURE:




PAX8e7-PPAR γ e1: AGA CCT ACC CCG TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

PAX8e8-PPAR γ e1: CGG GCC AGG CCC TCC TCT CAG -- AAA TGA CCA TGG TTG ACA CAG

PAX8e9-PPAR γ e1: CCA TCG CAG GCA TGG TGG CAG -- AAA TGA CCA TGG TTG ACA CAG

3 B. PAX8-PPAR γ mRNA:



3 C. PAX8-PPAR γ PROTEIN:






Figure 4

4A. PAX8-PPAR γ RTPCR:



4B. PAX8-PPAR γ IMMUNOHISTOCHEMISTRY:




anti-PPAR γ

anti-PPAR γ
+ PPAR γ peptide


4C.

THYROID NEOPLASM	RT-PCR	IMH
Follicular Carcinoma	5/8	7/8
Follicular Adenoma	0/20	0/20
Papillary Carcinoma	0/10	0/10
Multi-nodular Hyperplasia	0/10	0/10

THYROID FOLLICULAR CARCINOMA: t(2;3)(q13;p25)---->PAX8-PPAR γ



ACUTE PROMYELOCYTIC LEUKEMIA: t(15;17)(q22;q11-21) ----->PML-RAR α



ALVEOLAR RHABDOMYOSARCOMA: t(2;13)(q35;q14) ----->PAX3-FKHR





Figure 5

Figure 6

6 A.



6 B.

